Aware Super Pty Ltd as trustee of Aware Super Buys New Stake in United Therapeutics Corporation $UTHR

Aware Super Pty Ltd as trustee of Aware Super acquired a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 72,530 shares of the biotechnology company’s stock, valued at approximately $43,009,000. United Therapeutics comprises approximately 0.7% of Aware Super Pty Ltd as trustee of Aware Super’s portfolio, making the stock its 28th largest holding.

Other hedge funds have also recently bought and sold shares of the company. Geneos Wealth Management Inc. boosted its holdings in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of United Therapeutics by 18.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 70 shares during the last quarter. Jump Financial LLC acquired a new position in shares of United Therapeutics in the 2nd quarter valued at $277,000. Cerity Partners LLC grew its stake in shares of United Therapeutics by 77.3% during the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after buying an additional 5,600 shares during the period. Finally, Bank of Nova Scotia grew its stake in shares of United Therapeutics by 6.9% during the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 105 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several research reports. Royal Bank Of Canada increased their target price on United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Raymond James Financial assumed coverage on United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. Finally, Bank of America cut their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Ten equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $644.82.

United Therapeutics Stock Down 0.5%

United Therapeutics stock opened at $529.05 on Friday. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The firm has a fifty day moving average of $552.97 and a 200-day moving average of $530.10. The firm has a market capitalization of $22.46 billion, a P/E ratio of 19.53, a PEG ratio of 1.78 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same quarter in the previous year, the firm posted $6.63 EPS. The business’s revenue was down 1.6% compared to the same quarter last year. On average, research analysts expect that United Therapeutics Corporation will post 26.63 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $535.99, for a total value of $5,091,905.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $21,714,562.87. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jan Malcolm sold 325 shares of the business’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $550.59, for a total value of $178,941.75. Following the transaction, the director owned 450 shares in the company, valued at approximately $247,765.50. This represents a 41.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 564,743 shares of company stock worth $316,423,257. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.